Corticosteroids in Severe COVID-19(ASAP-C Study)

Administration of systemic corticosteroids for patients with severe forms of SARS-Co-2
infection are recommended by several guidelines. In the very beginning of SARS-Co-2
pandemic the early recommendation by professional organization was against routine use of
corticosteroids for patients with coronavirus disease 2019 (COVID-19) ARDS, despite
previous data and clinical practice for patients with refractory or severe form of ARDS.
But at the latest after publication of RECOVERY trial (Randomized Evaluation of Covid-19
Therapy, July 2020) and ensued metaanalysis of World Health Organization (WHO) working
group, the routine administration of systemic corticosteroids was revisited. However,
there are ongoing critical debate of the evidence regarding the dose, administration,
timing and type of corticosteroids and ongoing randomized controlled trial (RCT) are
challenging the recommendation of 6 mg of dexamethasone for all patients with severe form
of COVID-19. The dynamic of COVID-19 surges, flip-flop of official recommendations within
very short period of time and ongoing critical debate could be with possible variations
of daily clinical practice regarding using systemic corticosteroids. In an electronic
evaluation form that will be send to European Society of Intensive Care (ESICM) Members.
The electronic survey will contain 10 question. In the questionnaire the participants
will have to describe their routine clinical practice regarding administration of
systemic corticosteroids among patients with COVID-19 ARDS.